SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company witnessed a 19.04% growth in the revenue at Rs. 5835.76 millions for the quarter ended March 2022 as compared to Rs. 4902.51 millions during the year-ago period.The Company's Net profit for the March 2022 quarter have declined marginally to Rs. 827.19  millions as against Rs. 1025.07 millions reported during the corresponding quarter ended.Operating profit for the quarter ended March 2022 decreased to 1234.39 millions as compared to 1511.74 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 5835.76 4902.51 19.04 21898.76 18919.95 15.74 21898.76 18919.95 15.74
Other Income 18.56 253.04 -92.67 386.14 1118.89 -65.49 386.14 1118.89 -65.49
PBIDT 1234.39 1511.74 -18.35 5475.24 6682.54 -18.07 5475.24 6682.54 -18.07
Interest 15.77 6.83 130.89 49.49 71.92 -31.19 49.49 71.92 -31.19
PBDT 1218.62 1504.91 -19.02 5425.75 6610.62 -17.92 5425.75 6610.62 -17.92
Depreciation 217.86 161.92 34.55 712.82 673.55 5.83 712.82 673.55 5.83
PBT 1000.76 1342.99 -25.48 4712.93 5937.07 -20.62 4712.93 5937.07 -20.62
TAX 173.57 317.92 -45.40 1102.91 1466.23 -24.78 1102.91 1466.23 -24.78
Deferred Tax -136.43 32.92 -514.43 -122.09 91.23 -233.83 -122.09 91.23 -233.83
PAT 827.19 1025.07 -19.30 3610.02 4470.84 -19.25 3610.02 4470.84 -19.25
Equity 154.56 154.56 0.00 154.56 154.56 0.00 154.56 154.56 0.00
PBIDTM(%) 21.15 30.84 -31.40 25.00 35.32 -29.21 25.00 35.32 -29.21

JB Chem & Pharma Share Price

1997.35 22.65 (1.15%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×